Home » Stocks » GMDA

Gamida Cell Ltd. (GMDA)

Stock Price: $7.43 USD -0.22 (-2.88%)
Updated Apr 19, 2021 2:44 PM EDT - Market open
Market Cap 452.88M
Revenue (ttm) n/a
Net Income (ttm) -72.70M
Shares Out 59.20M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $7.43
Previous Close $7.65
Change ($) -0.22
Change (%) -2.88%
Day's Open 7.71
Day's Range 7.29 - 7.80
Day's Volume 270,718
52-Week Range 3.86 - 15.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chi...

1 week ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase 3...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for t...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will p...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a c...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that results from the Ph...

1 month ago - Business Wire

Recent clinical readouts could prove to be long-term growth catalysts for Novavax and Gamida Cell.

Other stocks mentioned: NVAX
2 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic diseases, today ann...

2 months ago - Business Wire

The company released data from a late-stage clinical trial.

2 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase 3...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of...

3 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will p...

3 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously anno...

3 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selecte...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-o...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conduct...

4 months ago - Business Wire

Early data for this company's natural killer cells is drawing lots of attention.

4 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today will be providing an update on the...

4 months ago - Business Wire

Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida CellĀ is a biopharmaceuti...

Other stocks mentioned: HOOK
4 months ago - Benzinga

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral presentation ...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that it will host a virtual ev...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Chief Execu...

4 months ago - Business Wire

Gamida Cell Ltd (GMDA) CEO Julian Adams on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for t...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-201, an inv...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chi...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that it will report its third quarter 2020 financial results and provide a company update on November 10, 2020.

5 months ago - Business Wire

Gamida Cell recently executed a secondary at $4.50 a share on the back of positive Phase 3 clinical data for its lead asset. The cell therapy biotech now trades at half its 2018 post IPO price despite a...

5 months ago - Seeking Alpha

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell and Be The Match BioTherapiesĀ® today announced an expansion of their strategic collaboration for investigational omidubicel.

6 months ago - Business Wire

Gamida Cell (GMDA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12 - 16, 2020.

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that its Phase 3 clinical study of omidubicel in bone marrow transplant met all three secondary endpoints.

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell today announced data from an observational study being presented at the virtual Cord Blood Connect Meeting.

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will participate in three upcoming virtual investor conferences in September.

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will host a two-part virtual miniseries in September focused on key topics related to its investigational cell therapy omidubicel.

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET.

8 months ago - Business Wire

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of Gamida Cell (NASDAQ:GMDA) moved higher by 1.6% in pre-market trading after the company reported Q2 results.

8 months ago - Benzinga

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

8 months ago - Zacks Investment Research

Is (GMDA) Outperforming Other Medical Stocks This Year?

8 months ago - Zacks Investment Research

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 28th

Other stocks mentioned: AAWW, AXU, NCNA
10 months ago - Zacks Investment Research

Gamida Cell (GMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 22nd

Other stocks mentioned: AAWW, CALM
10 months ago - Zacks Investment Research

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Gamida Cell has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and mu... [Read more...]

Industry
Biotechnology
IPO Date
Oct 26, 2018
Stock Exchange
NASDAQ
Ticker Symbol
GMDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Gamida Cell stock is "Buy." The 12-month stock price forecast is 19.00, which is an increase of 155.72% from the latest price.

Price Target
$19.00
(155.72% upside)
Analyst Consensus: Buy